[{"id":"5eec34c9-7beb-49a4-a2c7-9012b054777f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681287","created_at":"2021-01-19T20:46:42.670Z","updated_at":"2024-07-02T16:35:35.921Z","phase":"Phase 2","brief_title":"Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.","source_id_and_acronym":"NCT04681287","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • capecitabine • albumin-bound paclitaxel • vinorelbine tartrate • Cipterbin (inetetamab) • utidelone IV (UTD1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 11/04/2021","primary_completion_date":" 11/04/2021","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-09-25"},{"id":"ab67aa4e-3706-4bb1-9ddb-654da25dc17d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05328440","created_at":"2022-04-14T11:53:41.939Z","updated_at":"2024-07-02T16:35:35.894Z","phase":"Phase 2","brief_title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","source_id_and_acronym":"NCT05328440","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • EGFR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib) • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-09-25"},{"id":"f3babfe8-bc92-4caa-90a6-a8f28168e283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823623","created_at":"2023-04-21T15:04:29.768Z","updated_at":"2024-07-02T16:35:36.955Z","phase":"Phase 2","brief_title":"Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05823623","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Cipterbin (inetetamab) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/13/2022","start_date":" 02/13/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-14"},{"id":"d4952cfe-ac57-4d05-b6da-f3435de92c2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05980208","created_at":"2023-08-07T14:09:11.149Z","updated_at":"2024-07-02T16:35:40.610Z","phase":"","brief_title":"A Real-world Study of Inetetamab for First-line Treatment of MBC","source_id_and_acronym":"NCT05980208","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cipterbin (inetetamab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-08"},{"id":"377b4e35-1cd1-4d23-817b-8d168f800eb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05764941","created_at":"2023-03-13T15:02:10.833Z","updated_at":"2024-07-02T16:35:52.303Z","phase":"","brief_title":"Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05764941","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • vinorelbine tartrate • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-03-27"},{"id":"b577d973-1461-4df0-8561-a574d9c0851d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05749016","created_at":"2023-03-01T15:02:01.669Z","updated_at":"2025-02-25T13:55:00.149Z","phase":"Phase 2","brief_title":"Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer","source_id_and_acronym":"NCT05749016","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Perjeta (pertuzumab) • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-03-01"},{"id":"5d758cc2-f74d-40c5-a189-ed8157ad42a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429684","created_at":"2022-06-23T16:00:09.337Z","updated_at":"2025-02-25T13:54:29.757Z","phase":"Phase 3","brief_title":"Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer","source_id_and_acronym":"NCT05429684","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Ibrance (palbociclib) • everolimus • Tyvyt (sintilimab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • letrozole • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2022-06-23"},{"id":"850a25f1-f311-45e4-baf6-aa32f186b3d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05291910","created_at":"2022-03-23T13:53:26.937Z","updated_at":"2024-07-02T16:36:14.878Z","phase":"Phase 4","brief_title":"Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer","source_id_and_acronym":"NCT05291910","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Cipterbin (inetetamab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/12/2022","start_date":" 03/12/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-23"},{"id":"4edfcbdc-0916-406e-b371-1c0fc204eb00","acronym":"","url":"https://clinicaltrials.gov/study/NCT05131841","created_at":"2021-11-23T13:53:41.048Z","updated_at":"2024-07-02T16:36:20.338Z","phase":"Phase 4","brief_title":"Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC","source_id_and_acronym":"NCT05131841","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/04/2021","start_date":" 01/04/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-11-23"},{"id":"f8330f6b-8d91-4af1-ad20-74f268d6e530","acronym":"","url":"https://clinicaltrials.gov/study/NCT05016544","created_at":"2021-08-23T12:52:59.677Z","updated_at":"2024-07-02T16:36:26.017Z","phase":"Phase 1/2","brief_title":"Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05016544","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2021-08-23"},{"id":"2744bf5b-fe28-4693-864a-6febc125cb17","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963608","created_at":"2021-07-15T13:06:16.714Z","updated_at":"2024-07-02T16:36:27.851Z","phase":"","brief_title":"RWS of Inetetamab HER2 Positive Advanced Breast Cancer","source_id_and_acronym":"NCT04963608","lead_sponsor":"Zhiyong Yu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cipterbin (inetetamab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-07-15"},{"id":"e37ab4a9-1eb2-42bc-8b00-58aa1eb6ef78","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963595","created_at":"2021-07-15T13:06:16.474Z","updated_at":"2024-07-02T16:36:27.908Z","phase":"Phase 2","brief_title":"Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","source_id_and_acronym":"NCT04963595","lead_sponsor":"Zhiyong Yu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • vinorelbine tartrate • Cipterbin (inetetamab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2021-07-15"},{"id":"816bb58e-29fd-48d2-a464-7598271d2c9f","acronym":"Increase","url":"https://clinicaltrials.gov/study/NCT04941885","created_at":"2021-06-28T17:52:38.952Z","updated_at":"2024-07-02T16:36:28.363Z","phase":"Phase 2","brief_title":"Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer","source_id_and_acronym":"NCT04941885 - Increase","lead_sponsor":"Sun Yat-sen University","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 amplification • HER-2 negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Cipterbin (inetetamab) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-07-02"},{"id":"3ff6a5b1-214e-4af5-a89e-ebcc5422b1b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04736589","created_at":"2021-02-03T16:02:10.745Z","updated_at":"2024-07-02T16:36:35.121Z","phase":"Phase 3","brief_title":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","source_id_and_acronym":"NCT04736589","lead_sponsor":"Peking Union Medical College","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • MTOR mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • sirolimus • Cipterbin (inetetamab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2027","study_completion_date":" 02/02/2027","last_update_posted":"2021-02-03"},{"id":"8169fcff-ab24-4e73-97e1-0e9ba199e177","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681911","created_at":"2021-01-19T08:30:00.325Z","updated_at":"2024-07-02T16:36:36.931Z","phase":"Phase 2","brief_title":"Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT04681911","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • TP53 • TMB • CCND1 • ERBB4","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • TP53 • TMB • CCND1 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 09/09/2020","start_date":" 09/09/2020","primary_txt":" Primary completion: 09/09/2023","primary_completion_date":" 09/09/2023","study_txt":" Completion: 09/09/2024","study_completion_date":" 09/09/2024","last_update_posted":"2020-12-23"}]